Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis

Peritoneal Dialysis International

Volumn 26, Issue 1, 2006, Pages 53-63

  Pecoits Filho, Roberto ^a,c   Carvalho, Maria João ^a,b   Stenvinkel, Peter ^a   Lindholm, Bengt ^a   Heimbürger, Olof ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Inflammation; Interleukin 6; Peritoneal solute transport rate

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; BIOLOGICAL MARKER; DIALYSIS FLUID;

ACUTE DISEASE; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSATE LEVEL; DISEASE MARKER; EFFLUENT; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MALE; MORTALITY; PERITONEAL DISEASE; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; CHEMISTRY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; TIME; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; DIALYSIS SOLUTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745513606     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080602600109     Document Type: Article

References (30)

1. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43-58.
2. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
3. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003; 18:1042-5.
4. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-72.
5. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684-8.
6. Stenvinkel P, Chung SH, Heimbürger O, Lindholm B. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001; 21(Suppl 3):S157-62.
7. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20(Suppl 3):S5-96.
8. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
9. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-92.
10. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport rate an independent risk factor for CAPD mortality? Kidney Int 2000; 57:314-20.
11. Chung SH, Chu WS, Lee HA, Kim YH, Lee IS, Lindholm B, et al. Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000; 20:541-7.
12. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
13. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B. Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 1996; 49: 506-11.
14. Zemel D, Betjes MG, Dinkla C, Struijk DG, Krediet RT. Analysis of inflammatory mediators and peritoneal permeability to macromolecules shortly before the onset of overt peritonitis in patients treated with CAPD. Perit Dial Int 1995; 15:134-41.
15. Lai KN, Lai KB, Lam CW, Chan TM, Li FK, Leung JC. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35:644-52.
16. Breborowicz A, Oreopoulos DG. Evidence for the presence of chronic inflammation during peritoneal dialysis: therapeutic implications. Perit Dial Int 1997; 17(Suppl 2): S37-41.
17. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12:2146-57.
18. Stenvinkel P, Bárány P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002; 80:103-8.
19. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14.
20. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-18.
21. Wang T, Cheng HH, Heimbürger O, Bergström J, Lindholm B. Vasodilatation by intraperitoneal addition of nitroprusside is not a model for high peritoneal transport. Adv Perit Dial 1999; 15:53-9.
22. Witowski J, Jorres A, Coles GA, Williams JD, Topley N. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 1996; 50:1212-23.
23. Serre AF, Marie C, Beaujon G, Betail G, Cavaillon JM, Deteix P. Variations of cytokine levels and production in CAPD patients. Int J Artif Organs 1997; 20:614-21.
24. Plum J, Schoenicke G, Grabensee B. Osmotic agents and buffers in peritoneal dialysis solution: monocyte cytokine release and in vitro cytotoxicity. Am J Kidney Dis 1997; 30: 413-22.
25. Topley N, Williams JD. Effect of peritoneal dialysis on cytokine production by peritoneal cells. Blood Purif 1996; 14:188-97.
26. Mackenzie RK, Jones S, Moseley A, Holmes CJ, Argyle R, Williams JD, et al. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis 2000; 35:112-21.
27. Cooker L, Luneburg P, Holmes CJ, Topley N. Dialysate levels of IL-6 and VEGF in patients using bicarbonate/lactate-based peritoneal dialysis solutions [Abstract]. Perit Dial Int 2001; 21 (Suppl 2):S18.
28. Fujimori A, Naito H, Miyazaki T, Azuma M, Hashimoto S, Horikawa S, et al. Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron 1996; 74:471-2.
29. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16:2240-5.
30. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-39.